GlobeNewswire Inc. • Na Lexeo Therapeutics Announces Positive Interim Phase I/II Data for LX2020 for the Treatment of PKP2-Associated Arrhythmogenic Cardiomyopathy
01/12/2026 07:00 AM • Lexeo Therapeutics reported positive interim Phase I/II data for LX2020, an AAV-based gene therapy for PKP2-associated arrhythmogenic cardiomyopathy. The therapy demonstrated good tolerability across 10 participants, with 93-162% increases in PKP2 protein expression and stabilization or improvement in arrhythmia burden in the majority of participants. The company plans to complete 12-month data collection by Q4 2026 and engage with regulators in 2026.
TPR - Noted as a new partner in UK and Europe without specific performance context
LXEO - The company announced positive interim clinical trial data showing good safety profile, robust transduction, meaningful increases in PKP2 protein expression (93-162%), and clinically meaningful improvement or stabilization in arrhythmia burden across the majority of participants. No serious safety concerns were reported, and the therapy addresses an unmet medical need in a rare disease affecting approximately 60,000 people in the US.
LXEO - The company announced positive interim clinical trial data showing good safety profile, robust transduction, meaningful increases in PKP2 protein expression (93-162%), and clinically meaningful improvement or stabilization in arrhythmia burden across the majority of participants. No serious safety concerns were reported, and the therapy addresses an unmet medical need in a rare disease affecting approximately 60,000 people in the US.
#gene therapy
#AAV
#arrhythmogenic cardiomyopathy
#PKP2
#Phase I/II trial
#cardiac disease
#protein expression
#clinical trial data
Read More
Investing.com • Ali Merchant 
Benzinga • Lekha Gupta 
